Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Another win for brain centric obesity treatment approaches. Adding cagrilintide (an amylin analog) to semaglutide (a GLP 1 analog) enhances weight loss. 17.1% weight loss over 20 wk at highest dose, with weight still Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late Stage Trial: Novo Nordisk Update Patient Care Online Cagrilintide Semaglutide combo Improves Weight Loss and Glycemic Control in T2DM, finds trial